FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+

Infectious Disease Advisor·Jun 26

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

An FDA panel has backed Moderna's mRNA-based influenza vaccine for adults 50 and older. The vaccine, which uses mRNA technology, has received unanimous support from the panel. A full approval of the vaccine is expected, although the exact timing is not certain, with one report suggesting it could come by August.

Full coverage

FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence

Pharmacy Times·Jun 19

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

PBS·Jun 18

Moderna's mRNA flu vaccine backed by FDA advisers

Reuters·Jun 18

FDA Panel Backs Moderna's First mRNA Flu Shot — What It Could Mean for Your Fall Vaccine

Medical Daily·Jun 24

Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership

BioSpace·Jun 19

FDA Advisory Panel Backs Moderna's mRNA Flu Vaccine for Adults Aged 50 and Older

Medical Dialogues·Jun 21

FDA Panel Unanimously Backs Moderna mRNA Flu Vaccine: Full Approval Expected by August

Tech Times·Jun 19

FDA panel backs Moderna’s flu vaccine for older adults

Investing.com·Jun 18

View original report at Infectious Disease Advisor ↗

Fetching the latest headlines…